AJP - Renal Physiology, Vol 259, Issue 5 832-F838, Copyright © 1990 by American Physiological Society

ARTICLES

Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men

H. Saxenhofer, A. Raselli, P. Weidmann, W. G. Forssmann, A. Bub, P. Ferrari and S. G. Shaw
Medizinische Poliklinik, University of Berne, Switzerland.

Urodilatin is a newly identified analogue of human atrial natriuretic factor-(99-126) [ANF-(99-126)], which has recently been isolated from human urine and has 32 amino acid residues [ANF-(95-126)]. To investigate renal and cardiovascular effects in men, eight healthy subjects received injections of 25, 50, and 100 micrograms urodilatin iv compared with 50 micrograms ANF-(99-126) and placebo. Blood pressure decreased (P less than 0.05) after 50 micrograms ANF-(99-126), whereas urodilatin lowered diastolic blood pressure only at the highest dose (P less than 0.01). Heart rate increased (P less than 0.05-0.01) dose dependently after urodilatin injections. Glomerular filtration rate rose after 100 micrograms (from 120 +/- 3 to 156 +/- 7 ml.min-1.1.73 m-2, P less than 0.001) and 50 micrograms urodilatin (from 116 +/- 7 to 149 +/- 13 ml.min-1.1.73 m-2, P less than 0.01) but not after 25 micrograms urodilatin, ANF-(99-126), or placebo. Effective renal plasma flow was not significantly modified. Diuresis and excretion of sodium, chloride, and guanosine 3',5'-cyclic monophosphate increased (P less than 0.001) dose dependently; effects of 25 micrograms urodilatin equaled those of 50 micrograms ANF-(99-126). Plasma renin, aldosterone, and catecholamines were unchanged. We conclude that urodilatin can acutely modify renal and cardiovascular function in men and seems to exert more potent renal effects than ANF-(99-126).

This article has been cited by other articles:

				M. Heringlake, K. Wagner, J. Schumacher, and H. Pagel Urinary excretion of urodilatin is increased during pressure natriuresis in the isolated perfused rat kidney Am J Physiol Renal Physiol, September 1, 1999; 277(3): F347 - F351. [Abstract] [Full Text] [PDF]

				M. H. Bestle, N. V. Olsen, P. Christensen, B. V. Jensen, and P. Bie Cardiovascular, endocrine, and renal effects of urodilatin in normal humans Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1999; 276(3): R684 - R695. [Abstract] [Full Text] [PDF]

				M. Meyer, F. P. Armbruster, I. Maier, J. Schwing, C. Haller, A. Missbichler, K. Adermann, W.-G. Forssmann, and W. Woloszczuk Urinary and plasma urodilatin measured by a direct RIA using a highly specific antiserum Clin. Chem., December 1, 1998; 44(12): 2524 - 2529. [Abstract] [Full Text] [PDF]

				E. R. Levin, D. G. Gardner, and W. K. Samson Natriuretic Peptides N. Engl. J. Med., July 30, 1998; 339(5): 321 - 328. [Full Text] [PDF]

				W. Schmidt, A. Bub, M. Meyer, T. Weiss, G. Schneider, N. Maassen, and W. G. Forssmann Is urodilatin the missing link in exercise-dependent renal sodium retention? J Appl Physiol, January 1, 1998; 84(1): 123 - 128. [Abstract] [Full Text] [PDF]

				J. Sehested, B. Wacker, W.-G. Forssmann, and E. Schmitzer NATRIURESIS AFTER CARDIOPULMONARY BYPASS: RELATIONSHIP TO URODILATIN, ATRIAL NATRIURETIC FACTOR, ANTIDIURETIC HORMONE, AND ALDOSTERONE J. Thorac. Cardiovasc. Surg., October 1, 1997; 114(4): 666 - 671. [Abstract] [Full Text]